Company intelligence / Profile preview

CartilaGen

Likely Iowa City or nearby (University of Iowa affiliation), Iowa, United Statescartilagen.com ↗

Ownership: Private
Development stage: Preclinical

Overview

CartilaGen has developed an intra-articular injectable small-molecule therapy designed to prevent the onset of post-traumatic osteoarthritis. The company has received recognition and funding for its innovative approach but does not yet have published late-stage clinical results. It has won awards in entrepreneurial competitions and secured early-stage funding from organizations such as Wellmark and MATTER.

Therapeutic areas: Rheumatology
Modalities: Small moleculesdrug-eluting bioactive materials
Industry: Biotech

Partnerships

University of Iowa Research Foundation (technology licensing)

Beyond the preview

Go deeper on CartilaGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CartilaGen.

Explore the full profile